← brief for 2026-09-18 · Slowing decline

SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism.

Paper No results yet Peer reviewed

Key takeaways

This review looks at how a common diabetes drug affects blood and bones. It notes that the drug can raise blood cell counts and change bone minerals. It raises questions about how this might affect bone health in people with kidney disease. There are no new patient results in this review.

Who did this work

Mohammad AH · Mohammad SH · Alsaaty MH

Source

Paper · PubMed, the drug frontier · 2026 Aug 31
https://pubmed.ncbi.nlm.nih.gov/42754980/